Pancreas
14
1
2
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
21.4%
3 terminated out of 14 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Maternal Abdominal Morphology Assessment
Management of Symptomatic Advanced Pancreatic Adenocarcinoma
Is There a Pancreatic Segmentation Based on the Pancreatic Duct Branching?
Clinical Trial to Evaluate the Effectiveness and Safety of a Remote Automated Ultrasound Diagnostic System for Automated Ultrasound Examinations: a Prospective, Multicenter Study
Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies
Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.
Predictors of Postoperative Complications and Readmissions in Laparoscopic Pancreas Resection
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas
Radiation Therapy and Capecitabine/Oxaliplatin Chemotherapy in the Treatment of Locally Advanced Pancreas Adenocarcinoma
Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer
Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer